A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
about
Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientInhaled Antibiotics for Gram-Negative Respiratory InfectionsAerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial.How to approach and treat VAP in ICU patients.Ventilator-associated tracheobronchitis: pre-emptive, appropriate antibiotic therapy recommendedTreatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Aerosolized antibiotics: do they add to the treatment of pneumonia?Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination TherapyNebulizers for drug delivery to the lungs.Clinical pharmacokinetics of inhaled antimicrobials.Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?Challenges and opportunities in the treatment of ventilator-associated pneumonia.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.Aerosol delivery during invasive mechanical ventilation: a systematic review.In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model.Editorial Commentary: Antimicrobial De-escalation: What's in a Name?In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae.
P2860
Q26752680-324B7AC5-86D9-4079-9312-801463BF26DDQ28386160-7443767D-3A2B-4BB2-8B66-02DAE1367474Q33723207-05C03E65-DEE9-4063-925A-D066FD4CB22FQ35004845-7A0D4207-4788-4921-B07F-0466688F34A0Q35091915-758ACBF5-1245-4F7E-B7B8-5D33F12AD598Q36517624-E70F564B-E3E2-490B-AFEF-0BE018DD7751Q37271774-D1BC7563-9C7A-40E8-A498-FD09C74B18DAQ37538644-0FE08D15-E4E2-4B6E-B125-2C10EF1A955BQ38298171-BAB22EF2-D4B6-4DAE-97C6-AE1097E6E01CQ38367260-BBB7CCDE-3CA5-4DDF-9102-3A7AB057D5AFQ38447194-30546521-8ABF-47C6-B019-1DBE86A7655DQ38647453-978AD956-BFD1-4B5C-8E3A-5DEA0E9DB750Q38672016-563C6994-5DF7-49C4-900E-B7B98FFD14A0Q38835029-4D2138C1-9B1A-4D33-B726-2768023BD601Q38988630-68795E52-D216-4A73-86D1-4A1A4DFD8E44Q40121090-A62664A5-FDEA-4BB0-B62F-7906B1E13F01Q40401622-53D509EF-F8F3-4C0C-8D9E-F552C7B4CBCEQ40422166-57CE72C4-13E8-45C8-A4CD-FA99CAC4862FQ40578444-C460BFD8-223F-42E3-A3DA-D127E04D6E95Q41078268-CE2DDEB0-FC81-4D37-A9EA-B5D5880C3F3CQ41081119-E8D2ADDB-EB62-4192-AC09-9DDEAF1063ABQ42654272-C51397C8-0F98-40DC-85D2-55434624ABF8Q47240822-692ADDAD-7548-4DE0-AC7D-671C00D6341DQ53804008-ED6E0E5F-CF89-43BD-8797-85D4F67C1949Q55071894-95F0D9FD-02AE-47DB-9635-1747D65D2A7B
P2860
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized double-blind plac ...... hanically ventilated patients.
@ast
A randomized double-blind plac ...... hanically ventilated patients.
@en
A randomized double-blind plac ...... hanically ventilated patients.
@nl
type
label
A randomized double-blind plac ...... hanically ventilated patients.
@ast
A randomized double-blind plac ...... hanically ventilated patients.
@en
A randomized double-blind plac ...... hanically ventilated patients.
@nl
prefLabel
A randomized double-blind plac ...... hanically ventilated patients.
@ast
A randomized double-blind plac ...... hanically ventilated patients.
@en
A randomized double-blind plac ...... hanically ventilated patients.
@nl
P2093
P2860
P356
P1476
A randomized double-blind plac ...... hanically ventilated patients.
@en
P2093
A Bruce Montgomery
Andrew Davies
Markus Tservistas
Shirley Vallance
Tammy Abuan
P2860
P304
P356
10.1089/JAMP.2013.1100
P577
2014-12-01T00:00:00Z